ReviewMolecular therapy : the journal of the American Society of Gene Therapy2007
Advances in preclinical investigation of prostate cancer gene therapy.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Smart Nanobiomaterials for Gene Delivery in Localized Cancer Therapy: An Overview from Emerging Materials and Devices to Clinical Applications.Current cancer drug targets · 2025Review
- Oncolytic adenovirus-mediated therapy for prostate cancer.Oncolytic virotherapy · 2016Review
- AEG-1 promoter-mediated imaging of prostate cancer.Cancer research · 2014Article
- Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.Human gene therapy · 2013Article
- Nucleic acid-based approaches to STAT inhibition.JAK-STAT · 2012Review
- Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.Cancer research · 2011Article
- Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer.World journal of gastroenterology · 2011Article
- In vivo imaging of intraprostatic-specific gene transcription by PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011Article
- Experimental models to study lymphatic and blood vascular metastasis.Journal of surgical oncology · 2011Review
- Molecular markers in prostate cancer. Part II: potential roles in management.Asian journal of andrology · 2009Review
- Molecular markers in prostate cancer. Part I: predicting lethality.Asian journal of andrology · 2009Review
- Gene-modified bone marrow cell therapy for prostate cancer.Gene therapy · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Treating recurrent prostate cancer poses a great challenge to clinicians. Research efforts in the last decade have shown that adenoviral vector-based gene therapy is a promising approach that could expand the arsenal against prostate cancer. This maturing field is at the stage of being able to translate many preclinical discoveries into clinical practices. At this juncture, it is important to highlight the promising strategies including prostate-targeted gene expression, the use of oncolytic vectors, therapy coupled to reporter gene imaging, and combined treatment modalities. In fact, the early stages of clinical investigation employing combined, multimodal gene therapy focused on loco-regional tumor eradication and showed promising results. Clinicians and scientists should seize the momentum of progress to push forward to improve the therapeutic outcome for the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.